Hints and tips:
Related Special Reports
...SoftBank founder predicts WeWork V for Victory Masayoshi Son admitted today he had turned a “blind eye” to governance lapses at WeWork but promised a “sharp V-shaped recovery” for the shared offices provider...
...She cleaned the general office space, rather than the laboratories, according to her sworn declaration filed in the case....
...Last year, the Osaka-based drugmaker completed a $1.1bn acquisition of the generic drug business of US-based Upsher-Smith Laboratories, its first overseas purchase....
...One of his touchstones for anti-competitive behaviour is the late 1990s US v Microsoft case, in which the company was found guilty of using its operating system monopoly to stifle competitors like Netscape...
...Qubits v bytes: how quantum computing works Quantum computing taps into the quirky behaviour of sub-atomic particles, which bend our normal understanding of physics....
...He places human embryonic and pluripotent stem cells — that have the potential to grow into nearly every cell of the body — in tiny ‘U’ or ‘V’ shaped dishes in the lab to grow them into different types of...
...Thanks to a series of court rulings since the mid-2000s, such as eBay v MercExchange in 2007, Mayo Collaborative Services v Prometheus Laboratories in 2012 and Alice Corp v CLS Bank in 2014, and the subsequent...
...Impax Laboratories started selling mebendazole this year at an average wholesale price of $442 per pill, according to figures seen by the Financial Times, which were checked with several US pharmacy chains...
...Lannett Company, which has a market value of around $700m, dropped 19 per cent while Impax Laboratories (market cap $1.3bn) fell 12.4 per cent....
...Mr Saunders says that, in buying Whole Foods, Amazon is also acquiring a larger laboratory for its experiments in bricks-and-mortar retailing, which have multiplied over the past two years — but only on...
...The Federal Trade Commission accused it of paying $112m to Impax Laboratories in 2010 to delay for three years the introduction of a generic version of Opana ER, a controversial opioid-based painkiller that...
...AbbVie was previously forced to abandon a $55bn takeover of Ireland-based Shire as the US stepped up its efforts to crack down on so-called tax inversion deals, that see US companies move to more tax friendly...
...Turing Pharmaceuticals bought the rights to Daraprim from Impax Laboratories in August for $55m — a huge amount for a drug that has been available since 1953 — and quickly raised the price to recoup its...
...The only big winner, in terms of market capitalisation, has been Shire, whose growth has been based largely on drugs acquired through takeovers, principally in North America; it has few links with the UK...
...The largest deal of the year so far is Shire’s $32bn takeover of Baxalta....
...Shire’s pursuit of Baxalta marks a reversal of last year’s initially hostile bid for the UK-listed company by AbbVie, another Illinois-based drugmaker recently spun-off from Abbott Laboratories....
...UBS’s Mr Goodsall said Shire’s bid for Baxalta suggests big pharma may see opportunity in the blood plasma sector and could generate interest in CSL....
...The former was created last year when Abbott Laboratories spun off its research-based pharmaceuticals business from its medical devices and generic drugs....
...So would the new Mylan, which said on Monday that it would invert by purchasing European assets from Abbott Laboratories. The geography is dizzying....
...The company was spun off from Abbott Laboratories last year....
...Some say the greater entrepreneurial drive in the US helps commercialise scientific discoveries that in Europe might remain languishing in a university laboratory....
...For AbbVie, which was only created last year when Abbott Laboratories split its pharmaceuticals unit off – buying Shire would diversify its drug pipeline and allow it to access billions of dollars in foreign...
...The company was spun off from Abbott Laboratories last year. AbbVie and Shire declined to comment....
...Shire and AbbVie was not the only pharma deal of the week. In another so-called tax inversion, Mylan is to buy Abbot Laboratories’ European business....
International Edition